BMS-986325 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 53 | シェーグレン症候群 | 1 |
53. シェーグレン症候群
臨床試験数 : 283 / 薬物数 : 320 - (DrugBank : 101) / 標的遺伝子数 : 56 - 標的パスウェイ数 : 181
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04684654 (ClinicalTrials.gov) | February 16, 2021 | 22/12/2020 | BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome | A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Dose Study on the Safety, Pharmacokinetics, and Exploratory Pharmacodynamics of Subcutaneous and Intravenous BMS-986325 Administration in Healthy Participants and Participants With Primary Sjögren's Syndrome | Healthy Participants;Primary Sjögren's Syndrome | Biological: BMS-986325;Other: Placebo for BMS-986325 | Bristol-Myers Squibb | NULL | Recruiting | 18 Years | 65 Years | All | 136 | Phase 1 | Germany |